公开(公告)号：US20240082354A1

公开(公告)日：2024-03-14

申请号：US18513613

申请日：2023-11-19

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Ji Eun YANG ,  Do Hoon KIM ,  Sukyung KIM ,  Bo Ra SIM ,  Yunji LEE ,  Nayeon YANG ,  Junhwan KIM

IPC: A61K38/18 ,  A61P1/16

CPC classification number: A61K38/1841 ,  A61P1/16

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), comprising a GDF15 (growth differentiation factor-15) variant, a long-acting GDF15 fusion protein, or a long-acting GDF15 fusion protein dimer as an active ingredient.

公开(公告)号：US20210147386A1

公开(公告)日：2021-05-20

申请号：US17090552

申请日：2020-11-05

Applicant: YUHAN CORPORATION

Inventor： Tae Han DONG ,  Yoo Hoi PARK ,  Tae Kyun KIM ,  Jae Eun JOO ,  Eun Hye Jung ,  Jae Won JEONG ,  Hyun Seung LEE ,  Do Hoon KIM ,  Ji Eun YANG ,  Jun Chul PARK ,  Sang Myoun LIM ,  Na Ry HA ,  Da In CHUNG ,  Ji Yeong GAL

IPC: C07D401/14 ,  C07D409/14 ,  C07D405/14 ,  C07D491/048 ,  C07D207/16 ,  C07D495/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. In particular, said compounds may be usefully applied in the treatment and prevention of FAP-mediated diseases.

公开(公告)号：US20240238380A1

公开(公告)日：2024-07-18

申请号：US18562322

申请日：2022-05-20

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Ji Eun YANG ,  Sukyung KIM ,  Bo Ra SIM ,  Yunji LEE ,  Do Hoon KIM ,  Mi Kyeong JU ,  Hyun Ho CHOI ,  Han Na HONG ,  Junhwan KIM

IPC: A61K38/26 ,  A61K38/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

CPC classification number: A61K38/26 ,  A61K38/1841 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes, obesity, dyslipidemia, or metabolic syndrome by administering in combination with a GLP-1 (glucagon-like peptide-1) receptor agonist, comprising a GDF15 (growth differentiation factor-15) variant, a long-acting GDF15 fusion protein, or a long-acting GDF15 fusion protein dimer as an active ingredient.